OncoSec Medical (ONCS) Trading Down 7.4%

OncoSec Medical Inc (NASDAQ:ONCS) was down 7.4% on Tuesday . The stock traded as low as $0.57 and last traded at $0.60. Approximately 738,743 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 553,963 shares. The stock had previously closed at $0.65.

Several equities research analysts have recently weighed in on ONCS shares. Zacks Investment Research upgraded OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Friday, March 15th. Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a report on Monday, April 1st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. OncoSec Medical has an average rating of “Buy” and a consensus target price of $3.13.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONCS. BlackRock Inc. increased its holdings in OncoSec Medical by 98.2% during the 4th quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 240,843 shares during the period. Geode Capital Management LLC increased its holdings in OncoSec Medical by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 163,405 shares during the period. Bank of New York Mellon Corp increased its holdings in OncoSec Medical by 484.1% during the 4th quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 83,150 shares during the period. Northern Trust Corp increased its holdings in OncoSec Medical by 33.6% during the 4th quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 28,914 shares during the period. Finally, Moloney Securities Asset Management LLC increased its holdings in OncoSec Medical by 117.4% during the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 27,000 shares during the period. Institutional investors own 6.38% of the company’s stock.

WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2019/04/16/oncosec-medical-oncs-trading-down-7-4.html.

OncoSec Medical Company Profile (NASDAQ:ONCS)

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

See Also: Is the QQQ ETF safe?

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit